Carregant...
SUN-LB036 Diabetic Ketoacidosis: A Rare Side Effect of Nivolumab Induced Insulin Dependent Diabetes Mellitus
Introduction: Nivolumab, is a monoclonal antibody directed against programmed cell death-1 receptor (anti PD-1), and is used in adjuvant treatment of melanoma. With the widespread use of immunotherapies, the incidence of autoimmune diseases referred to as immune related adverse events (irAE) is also...
Guardat en:
| Publicat a: | J Endocr Soc |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Endocrine Society
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6553046/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SUN-LB036 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|